Sino Biological and BioGeometry deepen strategic cooperation to empower Protein R&D with Generative AI in China

China-based Sino Biological has announced an expansion of its strategic partnership with BioGeometry, a pioneer in digital biology. This collaboration brings together Sino Biological's advanced protein expression and wet-lab capabilities with BioGeometry’s generative AI protein design and optimisation platform. The two companies aim to enhance their joint offerings and explore high-value market opportunities globally.

Sino Biological specialises in providing comprehensive, high-quality recombinant proteins and antibodies for life science research and innovative drug development. The company has established a one-stop CRO technical service platform covering gene cloning, protein expression, antibody development and production, and quality control research.

Deep learning, especially large-scale generative AI models, is transforming biomanufacturing. Following AlphaFold2's success in protein structure prediction, this year's AlphaFold3, using diffusion generative models, can predict structures for all biomolecules, gaining industry attention. Generative AI models like RFDiffusion have dramatically increased protein design success rates compared to traditional methods.

BioGeometry focuses on developing generative AI for protein design. Its team pioneered the use of diffusion models for molecular structure generation and published the influential "GeoDiff" in 2021. In June, BioGeometry launched GeoFlow, a protein foundation model capable of both structure prediction and design. GeoFlow rivals AlphaFold3 in antigen-antibody complex prediction and is freely available for non-commercial use. It is integrated into BioGeometry’sGeoBiologics platform, improving protein design with fewer experiments.